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Background: Hemeoxygenase-1 (HO-1) is an inducible heme degrading enzyme with antioxidant properties. Limited data suggest that HO-1 gene 
promoter polymorphisms and in-vivo HO-1 activity may confer protection against coronary artery disease (CAD). We aimed to assess whether HO-1 
promoter gene polymorphisms and HO-1 plasma levels could predict CAD presentation.
Methods: 264 patients with angiographically proven CAD (stenosis ≥50%; age=64±11 years) were classified into stable or unstable groups 
according to Braunwauld criteria. These patients were compared with an age- and sex-matched healthy control group (n=125, 62±10 years). 
All underwent HO-1 genotyping and were categorized as S/S (short/short) homozygotes, S/L (short/long) heterozygotes or L/L (long/long) 
homozygotes. HO-1 plasma level, serum ferritin, and high-sensitivity C-reactive protein (hsCRP) were measured.
Results: HO-1 promoter gene polymorphisms differed significantly between healthy and CAD groups with the prevalence of S/S homozygotes [(GT)
n <25 repeats] in controls 3 times higher than the CAD group (18% vs. 6%, p=0.001). Plasma HO-1 levels were higher in CAD patients than controls 
(58.1±18.9 vs. 36.7±11.1 ng/ml, p<0.0001), and higher still in unstable compared to stable patients (61.4±20.2 vs. 53.3±15.9 ng/ml, p=0.004). 
Compared with stable CAD, unstable patients had higher hsCRP (7.45 [2.6-18.1] vs. 2.2 [1.1-4.5], p<0.0001) and ferritin (172 [91-317] vs. 139 
[69-229.5], p=0.018). Among CAD patients, smoking status, HO-1 plasma levels, white cell count, hsCRP, and ferritin were univariate predictors of 
unstable presentation. Following multivariate analysis, HO-1 levels (OR 1.03, 95% CI 1.003-1.05, p=0.03), smoking status (OR 8.7, 95% CI 2.8-27.2, 
p<0.0001) and hsCRP (OR 2.6, 95% CI 1.8-3.9, p<0.0001) remained independent predictors of unstable CAD.
Conclusions: The HO-1 promoter gene polymorphism S/S appeared protective against CAD. Plasma HO-1 levels were raised in those with 
CAD particularly among unstable patients and independently predicted an unstable phenotype. These data suggest that HO-1 is upregulated in 
established CAD but further studies are needed to clarify its cardioprotective effects.
